Ameet Mallik finds greener turf as new head of ADC Therapeutics following ill-fated first CEO stint
Around a year ago, Ameet Mallik left his post at Novartis, where he had spent the last 16 years, to champion a drug for metastatic pancreatic cancer as CEO at Rafael Holdings. However, just half a year in, the company took a nosedive as that drug failed a Phase III trial, and Mallik, among many others, left his post at Rafael Holdings.
Now Mallik will be starting fresh as CEO of ADC Therapeutics, the company announced today.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.